ATE403635T1 - Verbindungen zur unterdrückung der hiv-tat- transaktivierung - Google Patents

Verbindungen zur unterdrückung der hiv-tat- transaktivierung

Info

Publication number
ATE403635T1
ATE403635T1 AT95933830T AT95933830T ATE403635T1 AT E403635 T1 ATE403635 T1 AT E403635T1 AT 95933830 T AT95933830 T AT 95933830T AT 95933830 T AT95933830 T AT 95933830T AT E403635 T1 ATE403635 T1 AT E403635T1
Authority
AT
Austria
Prior art keywords
sub
compounds
tat transactivation
hiv tat
suppressing hiv
Prior art date
Application number
AT95933830T
Other languages
German (de)
English (en)
Inventor
Ru Huang
John Gnabbe
Original Assignee
Univ Johns Hopkins
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Johns Hopkins filed Critical Univ Johns Hopkins
Application granted granted Critical
Publication of ATE403635T1 publication Critical patent/ATE403635T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/017—Esters of hydroxy compounds having the esterified hydroxy group bound to a carbon atom of a six-membered aromatic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C43/00—Ethers; Compounds having groups, groups or groups
    • C07C43/02—Ethers
    • C07C43/20—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring
    • C07C43/23—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring containing hydroxy or O-metal groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AT95933830T 1994-09-30 1995-09-22 Verbindungen zur unterdrückung der hiv-tat- transaktivierung ATE403635T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/316,341 US6365787B1 (en) 1994-09-30 1994-09-30 Compounds for the suppression of HIV TAT transactivation

Publications (1)

Publication Number Publication Date
ATE403635T1 true ATE403635T1 (de) 2008-08-15

Family

ID=23228649

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95933830T ATE403635T1 (de) 1994-09-30 1995-09-22 Verbindungen zur unterdrückung der hiv-tat- transaktivierung

Country Status (10)

Country Link
US (4) US6365787B1 (2)
EP (1) EP0783474B1 (2)
JP (2) JP3966900B2 (2)
CN (2) CN100413835C (2)
AT (1) ATE403635T1 (2)
AU (1) AU700481B2 (2)
CA (1) CA2200991C (2)
DE (1) DE69535804D1 (2)
ES (1) ES2312168T3 (2)
WO (1) WO1996010549A1 (2)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6365787B1 (en) * 1994-09-30 2002-04-02 The Johns Hopkins University Compounds for the suppression of HIV TAT transactivation
WO1999017609A1 (en) * 1997-10-07 1999-04-15 Larreacorp, Ltd. Nontoxic extract of larrea tridentata and method of making the same
US6608108B2 (en) * 1999-10-15 2003-08-19 Johns Hopkins University Method for treatment of tumors using nordihydroguaiaretic acid derivatives
US20030219407A1 (en) 2002-05-15 2003-11-27 The Regents Of The University Of California RNA silencing in animals as an antiviral defense
US7728036B2 (en) * 2003-05-20 2010-06-01 Erimos Pharmaceuticals, Llc Methods for delivery of catecholic butanes for treatment of tumors
US20060141029A1 (en) * 2003-05-20 2006-06-29 Erimos Pharmaceuticals Llc Methods and compositions for delivery of catecholic butanes for treatment of diseases
CN103585136A (zh) * 2003-05-20 2014-02-19 约翰霍普金斯大学 用于治疗肿瘤的邻苯二酚丁烷的释放的方法和组合物
CN100440843C (zh) * 2004-05-12 2008-12-03 华为技术有限公司 一种环网及其业务实现方法
US8440648B2 (en) * 2004-07-20 2013-05-14 Erimos Pharmaceuticals Llc Methods and compositions for treatment of intraepithelial neoplasia
CN101150955B (zh) * 2005-01-27 2013-04-17 埃里莫斯医药品有限公司 递送包括ndga化合物的儿茶酚丁烷的口服制剂
CA2595606C (en) * 2005-01-27 2014-12-16 Erimos Pharmaceuticals Llc Oral formulations for delivery of catecholic butanes including ndga compounds
KR20090006062A (ko) * 2006-02-23 2009-01-14 에리모스 파마슈티컬스 엘엘씨 인플루엔자 바이러스 감염의 치료 방법
US9067875B2 (en) 2006-10-02 2015-06-30 Erimos Pharmaceuticals Llc Tetra-substituted NDGA derivatives via ether bonds and carbamate bonds and their synthesis and pharmaceutical use
EP2076252B1 (en) * 2006-10-02 2014-04-02 Erimos Pharmaceuticals LLC Tetra-substituted ndga derivatives via ether bonds and carbamate bonds and their synthesis and pharmaceutical use
ES2588235T3 (es) * 2007-05-11 2016-10-31 Convatec Technologies Inc. Dispositivo de ostomía
US20100093872A1 (en) * 2008-10-15 2010-04-15 Erimos Pharmaceuticals Llc Stable aqueous formulations of water insoluble or poorly soluble drugs
WO2010054264A1 (en) * 2008-11-07 2010-05-14 Triact Therapeutics, Inc. Use of catecholic butane derivatives in cancer therapy
US20130331414A1 (en) * 2011-01-10 2013-12-12 Susana Valente Inhibitors of Retroviral Replication
JP6205373B2 (ja) * 2012-02-03 2017-09-27 ザ・ジョンズ・ホプキンス・ユニバーシティ Ｎｄｇａ誘導体およびソラフェニブを含む組成物、ならびにがんの処置におけるこれらの使用
CN104603094A (zh) * 2012-07-18 2015-05-06 约翰霍普金斯大学 通过四-o-甲基去甲二氢愈创木酸抑制bnip3以及预防和治疗缺血再灌注损伤的方法
JP6255038B2 (ja) 2013-02-26 2017-12-27 トリアクト セラピューティクス，インク． 癌治療
US9381246B2 (en) 2013-09-09 2016-07-05 Triact Therapeutics, Inc. Cancer therapy

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5276060A (en) * 1979-06-19 1994-01-04 Block/Chemex, G.P. Methods of treating tumors with compositions of catecholic butanes
US5008294A (en) 1985-02-11 1991-04-16 Chemex Pharmaceuticals, Inc. Methods of treating tumors with compositions of catecholic butanes
DE3009542A1 (de) 1980-03-13 1981-09-24 Henkel KGaA, 4000 Düsseldorf Desodorierende kosmetische zusammensetzungen
US4774229A (en) 1982-04-05 1988-09-27 Chemex Pharmaceuticals, Inc. Modification of plant extracts from zygophyllaceae and pharmaceutical use therefor
US4880637A (en) * 1985-02-11 1989-11-14 Chemex Pharmaceuticals, Inc. Compositions of catecholic butanes with zinc
FR2632956B2 (fr) * 1988-05-13 1991-07-12 Pasteur Institut Sondes a papillomavirus hpv49, hpv50, hpv54, hpv55; produits genetiquement et immunologiquement lies a ce papillomavirus hpv49, hpv50, hpv54, hpv55; procede de diagnostic in vitro d'infections a papillomavirus et d'immunisation in vivo contre ces papillomavirus
US5559149A (en) 1990-01-29 1996-09-24 Johnson & Johnson Consumer Products, Inc. Skin care compositions containing retinoids
US5195965A (en) * 1991-03-07 1993-03-23 Shantha Totada R Method and apparatus for localized treatment of human viral infections and cancers
US5646186A (en) 1994-05-17 1997-07-08 Johnson & Johnson Consumer Products, Inc. Retinoid composition
US5409690A (en) * 1993-06-23 1995-04-25 Chemex Pharmaceuticals, Inc. Treatment of multidrug resistant diseases in cancer cell by potentiating with masoprocol
US6365787B1 (en) * 1994-09-30 2002-04-02 The Johns Hopkins University Compounds for the suppression of HIV TAT transactivation
US6071949A (en) 1995-03-14 2000-06-06 The United States Of America As Represented By The Department Of Health And Human Services Use of lipoxygenase inhibitors as anti-cancer therapeutic and intervention agents
US5837252A (en) * 1996-07-01 1998-11-17 Larreacorp, Ltd. Nontoxic extract of Larrea tridentata and method of making same
US5827898A (en) 1996-10-07 1998-10-27 Shaman Pharmaceuticals, Inc. Use of bisphenolic compounds to treat type II diabetes
US6245523B1 (en) 1996-11-20 2001-06-12 Yale University Survivin, a protein that inhibits cellular apoptosis, and its modulation
US6214874B1 (en) * 1999-10-15 2001-04-10 John Hopkins University Treatment of HPV induced cancer using in situ application of two nordihydroguiaretic acid derivatives, tetramethyl NDGA M4N and tetraglycinal NDGA G4N
US6608108B2 (en) * 1999-10-15 2003-08-19 Johns Hopkins University Method for treatment of tumors using nordihydroguaiaretic acid derivatives

Also Published As

Publication number Publication date
CA2200991C (en) 2007-07-10
AU700481B2 (en) 1999-01-07
USRE40246E1 (en) 2008-04-15
JPH10509421A (ja) 1998-09-14
JP2006273869A (ja) 2006-10-12
EP0783474B1 (en) 2008-08-06
WO1996010549A1 (en) 1996-04-11
CN1762951A (zh) 2006-04-26
CN100413835C (zh) 2008-08-27
CN1162301A (zh) 1997-10-15
EP0783474A4 (2) 1997-08-27
US6365787B1 (en) 2002-04-02
CA2200991A1 (en) 1996-04-11
ES2312168T3 (es) 2009-02-16
EP0783474A1 (en) 1997-07-16
JP3966900B2 (ja) 2007-08-29
AU3633995A (en) 1996-04-26
US5663209A (en) 1997-09-02
DE69535804D1 (de) 2008-09-18
US6291524B1 (en) 2001-09-18
CN1211335C (zh) 2005-07-20

Similar Documents

Publication Publication Date Title
ATE403635T1 (de) Verbindungen zur unterdrückung der hiv-tat- transaktivierung
DK0663892T3 (da) Plastificeringsmidler til vandige suspensioner af mineralpartikler og pastaer af hydraulisk bindemiddel
EE03194B1 (et) Ühendid, nende kasutamine magustavate toimeainetena ja nende valmistamise meetod
ES8300678A1 (es) Procedimiento de preparacion de derivados de 1-fenil-1-hi- droxi-etilamina
ES8308314A1 (es) Procedimiento para preparar derivados de 2-amino-4-hidroxiquinazolina.
ES8708232A1 (es) Procedimiento para la produccion de derivados de la 13-beta-milbemicina
ATE20051T1 (de) Amidinderivate, verfahren zu ihrer herstellung und diese enthaltende antikomplement-mittel.
TW363055B (en) Process for purifying crude (meth)acrylic acid
DK0915866T3 (da) Forbedret fremgangsmåde til syntese af beskyttende estere af (S)-3,4-dihydroxysmørsyre
ATE25974T1 (de) Acyl-substituierte derivate von 1,2,3,4tetrahydroisochinolin-3-carboxysaeuren, ihre salze, diese enthaltende arzneimittel und verfahren zu ihrer herstellung.
BG102048A (en) Tetrahydrofuran-containing sulphonamides as aspartylprotease inhibitors
BR9206552A (pt) Composto, processo para a preparação do mesmo, composição inseticida ou acaricida e processo de combater pregas de insetos ou acarinas
DK0669936T3 (da) Mercaptoacetylamidsubstitueret bicyklisk lactam til anvendelse som enkephalinase- og ACE-inhibitorer
EP1484059A3 (en) Antiviral composition comprising phenylacetic acid derivatives
ES8305298A1 (es) Un procedimiento para la preparacion de un isomero (25) del acido 2-(4-(2-hidroxiciclopentan-1-ilmetil)fenil)propionico.
JPS5414967A (en) Novel disazo compound and its preparation
DK287282A (da) Fremgangsmaade til fremstilling af adamantylethylaminer
ATE22011T1 (de) Virusimpfstoffe und verfahren zu ihrer herstellung.
JPS5271492A (en) Synthesis of 9-substituted-2-substituted thioadenines
GB1449147A (en) Prostaglandin intermediates method for electro coating metal surfaces with carbon
DK0672039T3 (da) Fremgangsmåde til fremstilling af alfa-aryl-gamma-butyrolactoner
DE69214280D1 (de) Thiocarbamat-sulfo-oxid enthaltende zubereitung zur abschreckung gegen ethanoleinnahme
AU572787B2 (en) Aphidicolin derivatives
JPS547427A (en) Novel disazo compounds and their preparation
IL116382A0 (en) Trisubstituted t hoxanthines and pharmaceutical compositions containing the same

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties